Anna-Maria Jegg

Title: Innovative Contributions of Anna-Maria Jegg in Cancer Therapy

Introduction

Anna-Maria Jegg, an accomplished inventor based in Penzberg, Germany, has made significant strides in the field of cancer treatment. She holds a patent that relates to novel therapeutic approaches targeting tumors, specifically after the failure of conventional treatment methods.

Latest Patents

Anna-Maria Jegg is the inventor of a patent titled "Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment." This invention presents a combination therapy that utilizes an anti-CSF-1R antibody, particularly a CSF-1R dimerization inhibitor, alongside an anti-PD-L1 antibody. This innovative therapy aims to address the challenges faced by patients who do not respond to existing PD-1/PD-L1 inhibitor treatments. The patent signifies a promising advance in pharmaceutical compositions aimed at enhancing the efficacy of cancer therapies.

Career Highlights

Anna-Maria Jegg currently works with Hoffmann-La Roche Inc., a leader in the biotechnology industry. Her role focuses on developing groundbreaking therapies for cancer treatment. With one patent to her name, she exemplifies the qualities of a dedicated and innovative scientist committed to improving patient outcomes.

Collaborations

Throughout her career, Anna-Maria has collaborated with esteemed colleagues, including Michael Cannarile and Francesca Michielin. These partnerships highlight the collaborative nature of research in the pharmaceutical field, where diverse expertise combines to foster innovation.

Conclusion

Anna-Maria Jegg's contributions to cancer therapy through her patent represent a significant advancement in the treatment of tumors. Her work, alongside that of her collaborators at Hoffmann-La Roche Inc., showcases the important role of inventors in the ongoing fight against cancer. Innovations like hers pave the way for future treatments that can better serve patients in need.